Name: ESLAW Income Statement - Estrella Immunopharma Revenue & EPS | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Revenue, Cost of Revenue, Gross Profit, Operating Expenses, Operating Income, Net Income, EPS Basic, EPS Diluted

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

ESLAW - Estrella Immunopharma, Inc.

USD | NASDAQ | Healthcare

ESLAW Income Statement - Estrella Immunopharma Revenue & EPS | Ledgeburg

(in millions of USD, except per-share data)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21
Revenues
Revenues	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses
Research & Development	1.4	0.0	4.2	4.7	1.4	(2.3)	2.8	0.0	-	0.5	2.6	-	2.6	-	-
Operating Income
Operating Income	(2.3)	(0.6)	(4.8)	(5.5)	(2.1)	0.5	(3.4)	(0.5)	(6.3)	(1.9)	(2.7)	1.9	(2.9)	(0.4)
Non-Operating
Interest Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	-
Tax & Net
Income Tax Expense	-	-	-	0.0	0.0	-	-	-	-	-	-	0.1	0.0	0.0	0.0
Per Share
EPS Basic	(0.05)	-	(0.13)	(0.15)	(0.06)	-	(0.09)	(0.01)	-	(1.78)	(8.13)	-	(34.33)	(0.06)	(0.02)	-
Supplementary Data
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD, except per-share data)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues
Revenues	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expenses
Research & Development	10.2	10.2	4.1	10.5	-	-
Selling General & Administrative	-	-	-	-	-	-
Operating Income
Operating Income	(13.3)	(13.1)	(7.3)	(11.1)	(1.6)	(0.2)
Non-Operating
Interest Income	-	-	-	-	0.7	0.0
Interest Expense	-	-	-	-	-	-
Income From Equity Investments
Tax & Net
Income Tax Expense	-	0.0	0.0	-	0.1	0.0
Net Income From Continuing Ops	(13.3)	(13.1)	(7.3)	(11.1)	(1.0)	(0.2)
Net Income From Discontinued Ops
Per Share
EPS Basic	(0.31)	(0.35)	(0.27)	(36.35)	-	-
EPS Diluted	(0.31)	(0.35)	(0.27)	(36.35)	-	-
Shares Basic
Supplementary Data
EBITDA	-	-	-	-	-	-
EBIT	(13.3)	(13.1)	(7.3)	(11.1)	(1.6)	(0.2)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)